Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 54822. Отображено 100.
05-01-2012 дата публикации

Recombinant fusion protein and polynucleotide construct for immunotoxin production

Номер: US20120003223A1
Автор: Itai Benhar, Yariv Mazor
Принадлежит: Ramot at Tel Aviv University Ltd

The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.

Подробнее
05-01-2012 дата публикации

Immunogenic compositions for inducing an immune response to hiv

Номер: US20120003265A1
Принадлежит: WYETH LLC

The invention relates to immunogenic compositions for inducing an immune response to HIV comprising combinations of two, three, or four plasmids, where each plasmid is expressing a defined antigen, which may be a single antigen or a fusion of two or three antigens.

Подробнее
12-01-2012 дата публикации

ANTI-Aß OLIGOMER HUMANIZED ANTIBODY

Номер: US20120009179A1
Принадлежит: Kyowa Hakko Kirin Co Ltd

An anti-Aβ oligomer humanized antibody which does not bind to Aβ monomers and specifically binds only to Aβ oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of Aβ amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.

Подробнее
19-01-2012 дата публикации

RNAi MOLECULE TARGETING THYMIDYLATE SYNTHASE AND APPLICATION THEREOF

Номер: US20120016012A1
Принадлежит: Delta Fly Pharma Inc

This invention provides a novel RNAi molecule that can significantly potentiate antitumor effects of a 5-FU antitumor agent. The RNAi molecule comprises the nucleotide sequence shown in SEQ ID NO: 2. The invention also provides an antitumor agent comprising such RNAi molecule and a 5-FU antitumor agent.

Подробнее
26-01-2012 дата публикации

Compositions and Methods for Induced Brown Fat Differentiation

Номер: US20120022500A1
Принадлежит: Dana Farber Cancer Institute Inc

The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of both Prdm1β and C/EBPβ activity and/or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of both Prdm1β and C/EBPβ expression and/or activity. Further provided are methods for identifying compounds that are capable of modulating both Prdm1β and C/EBPβ expression and/or activity.

Подробнее
16-02-2012 дата публикации

Compositions and methods for diagnosing prostate cancer based on detection of slc45a3-elk4 fusion transcript

Номер: US20120039887A1
Принадлежит: CORNELL UNIVERSITY

RNA transcripts representing a fusion of a human SLC45A3 nucleic acid and a human ELK4 nucleic acid that are associated with prostate cancer are described. Compositions and methods useful for detection of fusion transcripts of human SLC45A3 and ELK4 genetic sequences associated with cancer and useful for cancer therapy are provided.

Подробнее
01-03-2012 дата публикации

Vaccine composition for prophylaxis and/or therapy of alzheimer's disease

Номер: US20120052086A1
Принадлежит: Hokko Chemical Industry Co Ltd

A vaccine composition for prophylaxis and/or therapy of Alzheimer's disease, which comprises a fusion protein prepared by inserting a single or tandemly repeated multiple copies of amyloid β antigenic peptide having 5 to 15 continuous amino acid residues derived from the N-terminus of amyloid β peptide into a wild type seed storage protein.

Подробнее
15-03-2012 дата публикации

Eukaryotic host cell comprising an expression enhancer

Номер: US20120064630A1
Принадлежит: FH CAMPUS WIEN

Invention relates to a eukaryotic host cell comprising a recombinant nucleotide sequence encoding an expression enhancer, which is selected from the group consisting of cLC52, RPL33 and cLC61, and its use in a method of producing a protein of interest (POI).

Подробнее
29-03-2012 дата публикации

Control of Gene Expression Using a Complex of an Oligonucleotide and a Regulatory Peptide

Номер: US20120077270A1
Принадлежит: Imperial College Innovations Ltd

A method for suppressing the expression of a selected gene in a cell, the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an expression repressor portion, wherein the nucleic acid binding portion comprises an oligonucleotide or oligonucleotide mimic or analogue, and wherein the repressor portion comprises a polypeptide or peptidomimetic. Molecules for use in the methods of the invention are provided. The repressor may be a portion of a histone deacetylase or DNA methylase or polypeptide capable of recruiting a histone deacetylase or DNA methylase.

Подробнее
29-03-2012 дата публикации

Materials and Methods for the Treatment of Pathological Neovascularization in the Eye

Номер: US20120077870A1

The subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and diabetic retinopathy. In preferred embodiments, the subject invention provides materials and methods for effective treatment of pathological ocular neovascularization using gene therapy. In a specific embodiment the materials and methods of the subject invention can be used to treat AMD.

Подробнее
19-04-2012 дата публикации

Human artificial chromosome (hac) vector

Номер: US20120093785A1
Принадлежит: Kirin Brewery Co Ltd

The present invention relates to a human artificial chromosome (HAC) vector and a method for producing the same. The present invention further relates to a method for introducing foreign DNA using a human artificial chromosome vector and a method for producing a cell which expresses foreign DNA. Furthermore, the present invention relates to a method for producing a protein.

Подробнее
19-04-2012 дата публикации

Methods and compositions for enhanced gene expression through intron free energy reduction

Номер: US20120096583A1
Принадлежит: SYNGENTA PARTICIPATIONS AG

The present invention provides a method for selecting an intron for enhanced expression of a nucleotide sequence encoding a polypeptide, comprising: a) determining a mean free energy value per base pair of one or more introns; b) determining a mean IMEter score of the one or more introns of (a); and c) selecting an intron having a mean free energy value per base pair of below about −0.268 kcal/mol/bp and a mean IMEter score of at least about −0.034/bp, thereby selecting an intron for enhanced expression of a nucleotide sequence encoding the polypeptide, wherein expression of a nucleotide sequence operably associated with the selected intron is enhanced as compared to expression of a nucleotide sequence not operably associated with an intron having a mean free energy value per base pair of below about −0.268 kcal/mol/bp and a mean IMEter score of at least about −0.034/bp.

Подробнее
26-04-2012 дата публикации

CD86 Antagonist Multi-Target Binding Proteins

Номер: US20120100139A1

This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

Подробнее
26-04-2012 дата публикации

Anti-human cd52 immunoglobulins

Номер: US20120100152A1
Принадлежит: Genzyme Corp

The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.

Подробнее
26-04-2012 дата публикации

Subtilases

Номер: US20120101019A1
Принадлежит: Novozymes AS

The present invention relates to novel JP170 like subtilases from wild-type bacteria, hybrids thereof and to methods of construction and production of these proteases. Further, the present invention relates to use of the claimed subtilases in detergents, such as a laundry or an automatic dishwashing detergent.

Подробнее
24-05-2012 дата публикации

Inducible Expression System Transcription Modulators Comprising A Distributed Protein Transduction Domain And Methods For Using The Same

Номер: US20120129254A1
Принадлежит: Clontech Laboratories Inc

Aspects of the invention include inducible expression systems in which a transcription modulator having a distributed protein transduction domain is employed. Aspects of the invention further include methods of using the systems to induce expression of a coding sequence, as well as kits that find use in practicing methods of the invention. The systems, components thereof, methods and kits find use in a variety of different applications.

Подробнее
31-05-2012 дата публикации

Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination

Номер: US20120134993A1
Принадлежит: Zymogenetics Inc

Disclosed are bispecific binding proteins comprising a antibody/soluble receptor bispecific binding protein that reduces the biological activity of both VEGF-A and FGF. The FGF binding moieties are generally soluble FGFR3 or FGFR2. An Fc polypeptide is fused to the C-terminus of the FGF binding moiety and VEGF-A binding moiety are polypeptides fused using peptide or polypeptide linker sequences, and can be expressed as single bispecific binding protein. The bispecific antibody/soluble receptor binding proteins can be used to treat cancers characterized by solid tumor growth as well as other diseases.

Подробнее
31-05-2012 дата публикации

Nucleic acid molecule

Номер: US20120136184A1
Принадлежит: WWCC Ltd

The invention relates to an isolated nucleic acid molecule encoding a polypeptide capable of producing a triterpenoid hydrocarbon. The invention also relates to the encoded polypeptide, a vector comprising the nucleic acid molecule, a recombinant non-human organism comprising the nucleic acid molecule, and to methods of producing a triterpenoid hydrocarbon or an intermediate of biofuel using the nucleic acid molecule, polypeptide or recombinant organism.

Подробнее
31-05-2012 дата публикации

Constructs expressing chimeric receptors and use thereof for the controlled activation of defence response to pathogens in plants

Номер: US20120137392A1

The present invention relates to a construct able to express in at least one plant tissue, a chimeric receptor, said chimeric receptor being essentially made of the extracellular region, comprising the external juxtamembrane portion, of a first kinase receptor R1; and the transmembrane region and the intracellular region, comprising the internal juxtamembrane portion, of a second kinase receptor R2, wherein R1 and R2 are different and uses thereof.

Подробнее
07-06-2012 дата публикации

Immunogenic composition comprising antigenic s. aureus proteins

Номер: US20120141523A1
Принадлежит: GLAXOSMITHKLINE BIOLOGICALS SA

The present application relates to an immunogenic composition comprising a fragment of a staphylococcal Isd protein such as IsdA, IsdB, IsdC or IsdH which comprises a NEAT domain. Fusion proteins comprising a NEAT domain of a first staphylococcal Isd protein and a NEAT domain from a second Isd protein are also disclosed as well as fusion proteins comprising a NEAT domain of a staphylococcal Isd protein involved in an iron/heme uptake system and a ligand binding domain of a staphylococcal extracellular component binding protein, for example ClfA, ClfB, SdrC, SdrD or SdrE.

Подробнее
14-06-2012 дата публикации

Methods and compositions for seamless cloning of nucleic acid molecules

Номер: US20120149069A1
Принадлежит: Life Technologies Corp

The present invention is in the fields of biotechnology and molecular biology. More particularly, the present invention relates to cloning or subcloning one or more nucleic acid molecules comprising one or more type IIs restriction enzyme recognition sites. The present invention also embodies cloning such nucleic acid molecules using recombinational cloning methods such as those employing recombination sites and recombination proteins. The present invention also relates to nucleic acid molecules (including RNA and iRNA), as well as proteins, expressed from host cells produced using the methods of the present invention.

Подробнее
14-06-2012 дата публикации

Mesophilic and Thermophilic Organisms Modified to Produce Acrylate, and Methods of Use Thereof

Номер: US20120149077A1
Принадлежит: Mascoma Corp

The present invention provides for novel metabolic pathways leading to acrylate formation in a consolidated bio-processing system (CBP) where lignocellulosic biomass is efficiently converted to acrylate. In one such metabolic pathway, pyruvate is converted to lactate, which is converted to lactoyol-CoA, which is converted to acryloyl-CoA, and which is finally converted to acrylate. In another such metabolic pathway, pyruvate is converted to L-α-alanine, which is converted to L-aspartate, which is converted to β-alanine, which is converted to β-alanyl-CoA, which is converted to acryloyl-CoA, and which is finally converted to acrylate. In yet another metabolic pathway, pyruvate is converted to lactate, and then lactate is converted directly to acrylate. In certain aspects, the invention provides for heterologous expression of one or more enzymes in a mesophilic or thermophilic organism, such as Thermoanaerobacterium saccharolyticum or Clostridium thermocellutn , where the one or more enzymes functions within a novel metabolic pathway as described above to convert pyruvate to acrylate via lactate, or via β alanine and acryloyl-CoA.

Подробнее
21-06-2012 дата публикации

Method for inducing extended self-renewal of functionally differentiated somatic cells

Номер: US20120156179A1
Автор: Michael Sieweke

The present invention relates to a method for inducing proliferation of functionally differentiated somatic cells comprising a step of activating expression of a Myc family gene and a KIf family gene in said cells or contacting said cells with a Myc family protein and a KIf family protein.

Подробнее
28-06-2012 дата публикации

Cyclic di-amp induction of type i interferon

Номер: US20120164107A1
Принадлежит: UNIVERSITY OF CALIFORNIA

Methods of modulating type-I interferon production in a cell are provided. Aspects of the methods include modulating cytosolic cyclic di-adenosine monophosphate (c-di-AMP) activity in the cell in a manner sufficient to modulate type-I interferon production in the cell. Additional aspects of the invention include c-di-AMP activity modulatory compositions, e.g., c-di-AMP, mutant Listeria bacteria, cyclase and/or phosphodiesterase nucleic acid or protein compositions, etc. The subject methods and compositions find use in a variety of applications, including therapeutic applications.

Подробнее
12-07-2012 дата публикации

Screening of protein candidates

Номер: US20120178110A1
Принадлежит: NATIONAL RESEARCH COUNCIL OF CANADA

Successful application of an engineered protein as therapeutics or in other industries would require the protein to have good expression level, good biophysical properties and often desired affinity to its target. The present invention provides a method of screening large numbers of protein candidates (PCs) in all three aspects simultaneously. PCs are fused to a protein anchor, which is captured by the target/antigen. The captured PCs are evaluated for their expression levels, biophysical properties and affinities using conventional methods.

Подробнее
19-07-2012 дата публикации

Intracellular viral vector delivery method employing iron ion/viral vector composite

Номер: US20120183573A1

The present invention relates to an intracellular viral vector delivery method employing an iron ion/viral vector composite. The iron ion/viral vector composite according to the present invention is not dependent on the expression of CAR and so improves the efficiency of delivery of viral vectors and gene expression in cells of diverse types, and has an outstanding virus-neutralizing antibody escape performance, exhibits little cytotoxicity and is outstandingly stable even when subjected to iron ion processing at low concentration, and hence can be used to advantage in recombinant viral vaccine compositions.

Подробнее
26-07-2012 дата публикации

Method for a rational cell culturing process

Номер: US20120190005A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Biopharmaceutical process development with recombinant protein producing mammalian cells has realized a tremendous increase in both productivity and product yields in the past years. These achievements can be mainly attributed to the advancements in cell line development, media, and process optimization. Only recently, genome-scale technologies enable a system-level analysis to elucidate the complex biomolecular basis of protein production in mammalian cells promising an increased process understanding and the deduction of knowledge-based approaches for further process optimization. The present invention describes a method for a rational cell culturing process using such a knowledge-based approach.

Подробнее
26-07-2012 дата публикации

Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same

Номер: US20120190083A1
Принадлежит: CJ CHEILJEDANG CORP

The present invention provides methods for the production of cysteine or derivates thereof by culturing a microorganism having reduced activity of endogenous phosphoserine phosphatase and the activity of PhnC, PhnD, and PhnE is reduced, and enhanced activity of phosphoglycerate dehydrogenase and/or phosphoserine aminotransferase. The O-phosphoserine produced by such an organism can then be reacted with a sulfide in the presence of a sulfydrylase or a microorganism expressing a sulfhydrylase to produce cysteine or a derivative thereof. Microorganisms having these reduced and enhanced properties noted above are also provided herein.

Подробнее
26-07-2012 дата публикации

Methods and compositions for gene correction

Номер: US20120192301A1
Принадлежит: Sangamo Therapeutics Inc

Disclosed herein are methods and compositions for correction and/or mutation of genes associated with Parkinson's Disease as well as clones and animals derived therefrom.

Подробнее
06-09-2012 дата публикации

Regulated expression systems

Номер: US20120225933A1

The application relates to gene constructs for inducible hepato-specific expression of polynucleotides of interest in response to an inducer agent, said constructs comprising (i) an inducible bi-directional operator-promoter with at least one responsive element to said inducer agent flanked by two hepato-specific promoters acting in divergent manner, (ii) a first nucleotide sequence encoding a transactivator which may be activated by said inducer agent operatively coupled to the first hepato-specific promoter and (iii) a second nucleotide sequence operatively coupled to the second hepato-specific promoter, wherein the promoters are induced as a consequence of the binding of the transactivator to the operator region of the operator-promoter in the presence of the inducer agent.

Подробнее
13-09-2012 дата публикации

Fusion molecules and il-15 variants

Номер: US20120230946A1
Принадлежит: Altor Bioscience Corp

The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Подробнее
13-09-2012 дата публикации

NOVEL MULTIPLEX BARCODED PAIRED-END DITAG (mbPED) SEQUENCING APPROACH AND ITS APPLICATION IN FUSION GENE IDENTIFICATION

Номер: US20120231508A1
Принадлежит: Academia Sinica

A method of generating a barcoded Paired-End Ditag (bPED) nucleic acid fragment is disclosed. The method comprises: a) performing a first ligation by ligating a half-adaptor with one or two 3′-overhanging ends to a target nucleic acid to obtain a nucleic acid fragment with two ends each attached to one of the half-adaptor, the half adaptor comprising a half-barcode and a restriction enzyme (RE) recognition site; b) performing a second ligation by ligating two of the half-adaptor at the two ends of the nucleic acid fragment to form a circularized nucleic acid construct, wherein the circularized nucleic acid construct comprises a full-size barcoded adaptor; and c) digesting the circularized nucleic acid construct with a RE that cleaves at a defined distance from the RE recognition site, and thereby generating the bPED nucleic acid fragment.

Подробнее
20-09-2012 дата публикации

Anti-Microbial Biotherapeutic Agents: Alternatives to Conventional Pharmaceutical Antibiotics

Номер: US20120238024A1
Автор: Marcin S. Filutowicz
Принадлежит: Individual

Novel antimicrobial agents that can serve as replacements to conventional pharmaceutical antibiotics are disclosed. The antimicrobial agents comprise conjugatively transmissible plasmids that kill targeted pathogenic bacteria, but are not harmful to donor bacteria. Two types of lethal transmissible plasmids are disclosed. One type kills recipient bacteria by unchecked (“runaway”) replication in the recipient cells and is prevented from occurring in donor cells. Another type kills recipient bacteria by expressing a gene that produces a product detrimental or lethal to recipient bacterial cells, that gene being prevented from expression in donor cells.

Подробнее
27-09-2012 дата публикации

Riboswitch based inducible gene expression platform

Номер: US20120244601A1
Принадлежит: UNIVERSITY OF CALIFORNIA

The present disclosure provides a synthetic translation regulator, as well as gene expression cassettes and gene expression constructs comprising the synthetic translation regulator. The present disclosure further provides genetically modified bacterial host cells comprising a subject synthetic translation regulator; and methods of regulating gene expression in such host cells.

Подробнее
04-10-2012 дата публикации

Optimized messenger rna

Номер: US20120252117A1
Принадлежит: Individual

The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.

Подробнее
11-10-2012 дата публикации

HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha

Номер: US20120258114A1
Принадлежит: ABBVIE BIOTECHNOLOGY LTD

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Подробнее
01-11-2012 дата публикации

Diacylglycerol acyltransferase genes and use thereof

Номер: US20120277451A1
Автор: Misa Ochiai
Принадлежит: Suntory Holdings Ltd

It is an object to provide a novel diacylglycerol acyltransferase. The present invention relates to a diacylglycerol acyltransferase, a polynucleotide encoding the same, and so on. The present invention provides a polynucleotide comprising the nucleotide sequence of, e.g., SEQ ID NO: 1 or 4, a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2, an expression vector and transformant comprising the polynucleotide, a method for producing a lipid or fatty acid composition using the transformant, or a food, etc. comprising the lipid or fatty acid produced by the method.

Подробнее
22-11-2012 дата публикации

Sulfonylurea-responsive repressor proteins

Номер: US20120295354A1
Принадлежит: EI Du Pont de Nemours and Co

Compositions and methods relating to the use of sulfonylurea-responsive repressors are provided. Compositions include polypeptides that specifically bind to an operator, wherein the specific binding is regulated by a sulfonylurea compound. Compositions also include polynucleotides encoding the polypeptides as well as constructs, vectors, prokaryotic and eukaryotic cells, and eukaryotic organisms including plants and seeds comprising the polynucleotide, and/or produced by the methods. Also provided are methods to provide a sulfonylurea-responsive repressor to a cell or organism, and to regulate expression of a polynucleotide of interest in a cell or organism, including a plant or plant cell.

Подробнее
29-11-2012 дата публикации

Biological synthesis of difunctional hexanes and pentanes from carbohydrate feedstocks

Номер: US20120301950A1
Принадлежит: Celexion LLC, Codon Devices Inc

Provided herein are methods for the production of difunctional alkanes in microorganisms. Also provided are enzymes and nucleic acids encoding such enzymes, associated with the difunctional alkane production from carbohydrates feedstocks in microorganisms. The invention also provides recombinant microorganisms and metabolic pathways for the production of difunctional alkanes.

Подробнее
29-11-2012 дата публикации

Method for screening ameliorants of dry skin caused by atopic dermatitis using bleomycin hydrolase activity as indicator

Номер: US20120302649A1
Принадлежит: Shiseido Co Ltd

The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug.

Подробнее
06-12-2012 дата публикации

Antibodies specific for claudin 6 (cldn6)

Номер: US20120308478A1

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Подробнее
06-12-2012 дата публикации

Methods and compositions for nucleic acid sample preparation

Номер: US20120309650A1
Принадлежит: Pacific Biosciences of California Inc

Provided are methods and compositions for the production of linear single-stranded nucleic acids, which can be used as templates in high-throughput sequencing systems. Also provided are methods and compositions for the production of closed single-stranded nucleic acid loops, which can be used as templates in high-throughput sequencing systems.

Подробнее
06-12-2012 дата публикации

Production of Therapeutic Proteins in Photosynthetic Organisms

Номер: US20120309939A1

The present disclosure relates to methods of expressing therapeutic proteins in photosynthetic organisms and the therapeutic proteins produced by the methods. The therapeutic proteins include high-mobility group box 1 (HMGB1) protein, fibronectin domain (10) (10FN3), fibronectin domain (14) (14FN3), interferon beta (IFNβ), proinsulin and vascular endothelial growth factor (VEGF). The photosynthetic organisms include prokaryotes such as cyanobacteria and eukaryotes such as alga and plants. Transformation of eukaryotes is preferably the plastid genome, more preferably the chloroplast genome.

Подробнее
20-12-2012 дата публикации

Novel chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof

Номер: US20120321653A1

The present invention provides a chimeric polypeptide comprising a plurality of polypeptide domains that are capable of being secreted in combination with membrane vesicles and in particular exosomes. The invention also concerns the use of polypeptides of the invention and polynucleotides coding for these polypeptides, for the production of immunogenic compositions based on exosomes or DNA, to screen protein interactions. The present invention also concerns exploiting the properties of exosomes comprising a polypeptide of the invention and immunogenic compositions of the invention in immunology. The present invention concerns the use of exosomes comprising a polypeptide of the invention as a diagnostic tool. The present invention also concerns exploiting the properties of membrane vesicles and protein compositions of the invention for the prophylaxis and/or treatment of a disease due to a functional deficit, in particular to transport a protein or a nucleic acid, in particular to compensate for or make up for an enzymatic deficit, or in particular to induce a transcriptional or translational modification in the target cells or organs.

Подробнее
20-12-2012 дата публикации

Group a streptococcus multivalent vaccine

Номер: US20120321657A1
Автор: James B. Dale

Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A streptococcus (GAS). Immunogenic compositions provided herein are multivalent and comprise a plurality of immunogenic peptides or fusion polypeptides comprising the immunogenic peptides that induce an immune response against GAS. The immunogenic compositions provided herein induce an immune response against the GAS serotypes represented by an immunogenic peptide (derived from an M protein or Spa protein) comprised within the immunogenic composition and also induce an immune response against serotypes that are unrepresented by any immunogenic peptide included in the immunogenic composition. Methods for using the compositions for inducing an immune response against GAS and for treating or reducing the likelihood of occurrence of a GAS infection are also provided.

Подробнее
20-12-2012 дата публикации

Novel Ecdysone Receptor-Based Inducible Gene Expression System

Номер: US20120322148A1
Принадлежит: Intrexon Corp

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.

Подробнее
03-01-2013 дата публикации

Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses

Номер: US20130004505A1
Принадлежит: Celltrion Inc

The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection.

Подробнее
03-01-2013 дата публикации

Two-way, portable riboswitch mediated gene expression control device

Номер: US20130004980A1
Автор: Jian-Dong Huang, Ye Jin
Принадлежит: University of Hong Kong HKU

A regulatable gene expression construct comprising a nucleic acid molecule comprising a two-way riboswitch operably linked to a target sequence. Also provided is a library screening strategy for efficient creation of target-specific riboswitches. A theophylline-repressible and IPTG-inducible riboswitch device achieves portable control of gene expression control in a ‘two-way’ manner. The default state of target genes is ON; the targets are switched off by adding theophylline, and switched back to the ON-state by adding IPTG without changing growth medium. The riboswitch device regulates gene expression in a portable, adjustable, and two-way manner with a variety of scientific and biotechnological applications.

Подробнее
03-01-2013 дата публикации

Nucleic acid encoding reactions

Номер: US20130005585A1
Принадлежит: Fluidigm Corp

Described herein are methods useful for incorporating one or more adaptors and/or nucleotide tag(s) and/or barcode nucleotide sequence(s) one, or typically more, target nucleotide sequences. In particular embodiments, nucleic acid fragments having adaptors, e.g., suitable for use in high-throughput DNA sequencing are generated. In other embodiments, information about a reaction mixture is encoded into a reaction product. Also described herein are methods and kits useful for amplifying one or more target nucleic acids in preparation for applications such as bidirectional nucleic acid sequencing. In particular embodiments, methods of the invention entail additionally carrying out bidirectional DNA sequencing. Also described herein are methods for encoding and detecting and/or quantifying alleles by primer extension.

Подробнее
03-01-2013 дата публикации

Synthetic biology tools

Номер: US20130005590A1
Принадлежит: UNIVERSITY OF CALIFORNIA

Methods for design of genetic circuits are provided.

Подробнее
17-01-2013 дата публикации

Methods and compositions for enhanced expression and secretion of proteins

Номер: US20130017574A1
Автор: Xiaowu Liu, Zhuying Wang

Optimized signal peptide coding sequences for enhanced expression and secretion of protein from a cell and related compositions and methods are described. The optimized signal peptide coding sequence encodes an mRNA that contains at least one hairpin structure immediately downstream of the initiation codon. Methods for obtaining the optimized signal peptide coding sequences and methods for enhanced expression and secretion of proteins using the optimized signal peptide coding sequences are also described.

Подробнее
24-01-2013 дата публикации

New composition and methods for treatment of autoimmune and allergic diseases

Номер: US20130022634A1
Автор: Nils Lycke
Принадлежит: TOLERANZIA AB

The present invention provides improved methods and compositions for treating and preventing autoimmune and allergic diseases. More specifically, the invention relates to new immunomodulating complexes that are fusion proteins comprising a mutant subunit of the A1-subunit of the cholera toxin (CTA1), a peptide capable of binding to a specific cellular receptor, and one or more epitopes associated with an autoimmune or allergic disease. In the mutant CTA1 subunit, the amino acids corresponding to the amino acid 7, arginine, and amino acid 187, cysteine, in the native CTA1 have been replaced.

Подробнее
31-01-2013 дата публикации

Antagonist anti-il-7 receptor antibodies and methods

Номер: US20130028916A1
Принадлежит: Rinat Neuroscience Corp

The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.

Подробнее
31-01-2013 дата публикации

Albumin Derivatives and Variants

Номер: US20130028930A1
Принадлежит: Novozymes Biopharma DK AS

The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.

Подробнее
31-01-2013 дата публикации

Glycine riboswitches, methods for their use, and compositions for use with glycine riboswitches

Номер: US20130029342A1
Принадлежит: YALE UNIVERSITY

Riboswitches are structural elements in mRNA that change state when bound by a trigger molecule, and are thus able to regulate gene expression. They can be dissected into two separate domains: one that selectively binds the target (aptamer domain) and another that influences genetic control (expression platform domain). Bacterial glycine riboswitches consist of two tandem aptamer domains which cooperatively bind glycine to regulate the expression of downstream genes. These natural switches are targets for antibiotics and other small molecule therapies. Modified versions of these natural riboswitches can be employed as designer genetic switches that are controlled by specific effector compounds. Disclosed are isolated and recombinant riboswitches, and compositions and methods for selecting and identifying compounds that can activate, inactivate, or block a riboswitch.

Подробнее
07-02-2013 дата публикации

Interleukin-12 P40 Variants with Improved Stability

Номер: US20130034518A1
Принадлежит: Merck Patent GmBH

Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.

Подробнее
07-02-2013 дата публикации

Biological circuit chemotactic converters

Номер: US20130034907A1

Described herein are novel biological circuit chemotactic converter that utilize modular components, such as genetic toggle switches and single invertase memory modules (SIMMs), for detecting and converting external inputs, such as chemoattractants, into outputs that allow for autonomous chemotaxis in cellular systems. Flexibility in these biological circuit chemotactic converter is provided by combining individual modular components, i.e., SIMMs and genetic toggle switches, together. These biological converter switches can be combined in a variety of network topologies to create network systems that regulate chemotactic responses based on the combination and nature of input signals received.

Подробнее
21-02-2013 дата публикации

Biologic female contraceptives

Номер: US20130045184A1
Автор: Rachel Teitelbaum
Принадлежит: Individual

This invention provides, inter alia, commensal organisms engineered to express antibody fragments, which inhibit sperm motility or fertilization and compositions comprising the same. The present invention provides for the use of the engineered commensal organisms or compositions comprising the same as effective contraceptive means in females.

Подробнее
21-02-2013 дата публикации

Isoprene synthase variants for improved production of isoprene

Номер: US20130045891A1
Принадлежит: DANISCO US INC

The present invention provides methods and compositions comprising at least one isoprene synthase enzyme with improved specific productivity. In particular, the present invention provides variant plant isoprene synthases for increased isoprene production in host cells.

Подробнее
07-03-2013 дата публикации

Compositions and methods for use in recombinational cloning of nucelic acids

Номер: US20130059342A1
Принадлежит: Life Technologies Corp

The present invention relates to compositions and methods for use in recombinational cloning of nucleic acid molecules. In particular, the invention relates to nucleic acid molecules encoding one or more recombination sites or portions thereof, to nucleic acid molecules comprising one or more of these recombination site nucleotide sequences and optionally comprising one or more additional physical or functional nucleotide sequences. The invention also relates to vectors comprising nucleic acid molecules of the invention, to host cells comprising vectors or nucleic acid molecules of the invention, to methods of producing polypeptides using nucleic acid molecules of the invention, and to polypeptides encoded by these nucleic acid molecules or produced by methods of the invention. The invention also relates to the use of these compositions in methods for recombinational cloning of nucleic acids, in vitro and in vivo, to provide chimeric DNA molecules that have particular characteristics and/or DNA segments.

Подробнее
14-03-2013 дата публикации

Engineered anti-il-23r antibodies

Номер: US20130064817A1
Автор: Leonard G. Presta
Принадлежит: Merck Sharp and Dohme LLC

Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.

Подробнее
14-03-2013 дата публикации

Tumor-specific promoter and oncolytic virus vector comprising the same

Номер: US20130065952A1

Provided are tumor-specific promoters, oncolytic virus vectors and a pharmaceutical composition comprising the virus vector. The virus vector comprising the novel tumor-specific promoter shows excellent oncolytic effects on tumor cells, and thus it is useful for treating a cancer.

Подробнее
14-03-2013 дата публикации

ENGINEERED RED-SHIFTED CHANNELRHODOPSIN VARIANTS

Номер: US20130066402A1

The invention provides engineered red-shifted channelrhodopsin variants. In some embodiments, the channelrhodopsin variants are characterized by improved membrane trafficking, expression, and/or unique spectral and kinetic properties. 1Volvox carteriVolvox carteri. A polypeptide comprising a channelrhodopsin-1 (ChR1) domain , a channelrhodopsin-1 (VChR1) domain and a channelrhodopsin-2 (VChR2) domain.2. The polypeptide of claim 1 , wherein the polypeptide has the structure:{'sup': 1', '2', '3', '4, 'X-X-X-X'}{'sup': '1', 'wherein Xis a ChR1 domain,'}{'sup': '2', 'Xis a first VChR1 domain,'}{'sup': '3', 'Xis a VChR2 domain and'}{'sup': '4', 'Xis a second VChR1 domain.'}3. The polypeptide of claim 1 , having a sequence according to SEQ ID NO: 1.4. The polypeptide of claim 2 , wherein one or more of the domains X claim 2 , X claim 2 , X claim 2 , and Xcomprises 1 claim 2 , 2 claim 2 , 3 claim 2 , 4 claim 2 , or 5 amino acid substitutions relative to a corresponding wild-type domain.5. The polypeptide of claim 4 , wherein the amino acid substitution is at one or more positions selected from 163 claim 4 , 171 claim 4 , 174 and 266.6. The polypeptide of claim 4 , comprising one or more amino acid substitutions selected from Glu163Thr claim 4 , Leu171Ile claim 4 , Leu171Val claim 4 , His174Arg claim 4 , and Phe266Tyr.7. The polypeptide of further comprising a fluorescent polypeptide.8. A polynucleotide encoding the polypeptide of .9. The polynucleotide of claim 8 , having a sequence according to SEQ ID NO: 2.10. A method of depolarizing a cell comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) expressing the polypeptide of within the cell; and'}(b) exposing the cell to light.11. (canceled)12. (canceled)13. A method of restoring sensitivity to light in an ocular cell comprising expressing the polypeptide of in the ocular cell.14. The polypeptide of claim 1 , comprising an amino acid sequence that is at least 85% identical to SEQ ID NO:1.15. The polypeptide of ...

Подробнее
21-03-2013 дата публикации

INSULIN-LIKE GROWTH FACTOR II (IGF-II) BINDING FACTORS

Номер: US20130071366A1
Принадлежит: Cancer Research Technology Limited

This invention relates to modified IGF-II binding domains of the Insulin-like Growth Factor 2 Receptor (IGF2R) which have enhanced binding affinity for IGF-II relative to the wild type IGF-II binding domain. Suitable IGF-II binding domains may be modified, for example, by substituting residue E1544 for a non-acidic residue. These modified domains may be useful in the sequestration of Insulin-like Growth Factor II (IGF-II), for example, in the treatment of cancer. 125-. (canceled)26. A mutant IGF-II binding domain comprising an amino acid sequence that has at least 80% sequence identity with residues 1511 to 1650 of human IGF2R ,wherein residue E1544 is substituted for a non-acidic residue, andwherein said binding domain binds IGF-II with increased affinity relative to residues 1511 to 1650 of human IGF2R.27. The mutant IGF-II binding domain of claim 26 , wherein the binding domain does not bind or does not substantially bind to IGF1.28. The mutant IGF-II binding domain of claim 26 , wherein the mutated residues are mutated by substitution claim 26 , insertion or deletion.29. The mutant IGF-II binding domain of claim 26 , wherein residue E1544 is substituted for a basic residue.30. The mutant IGF-II binding domain of claim 29 , wherein residue E1544 is substituted for K.31. The mutant IGF-II binding domain of claim 29 , wherein residue E1544 is substituted for R.32. The mutant IGF-II binding domain of claim 29 , wherein residue E1544 is substituted for H.33. The mutant IGF-II binding domain of claim 29 , wherein residue E1544 is substituted for S.34. The mutant IGF-II binding domain of claim 26 , wherein residues F1567 and I1572 are not mutated.35. The mutant IGF-II binding domain of claim 34 , wherein residue T1570 is not mutated.36. The mutant IGF-II binding domain of claim 34 , wherein residues P1597 and P1599 are not mutated.37. The mutant IGF-II binding domain of claim 26 , wherein the binding domain consists of the amino acid sequence of residues 1511 to 1650 ...

Подробнее
21-03-2013 дата публикации

METHODS FOR PRODUCING ANTIBODY-PRODUCING CELLS THAT PRODUCE DESIRED POLYPEPTIDES

Номер: US20130071881A1
Принадлежит: Immuno Tec Laboratory Co. Ltd

An objective of the present invention is to provide methods for introducing DNAs encoding a desired amino acid sequence into a region comprising a DNA encoding an antibody variable region of antibody-producing cells. The present inventors developed methods for efficiently introducing DNAs encoding a desired amino acid sequence into the antibody variable region gene locus of DT40-SW, which is a mutant line of the DT40 chicken B cell line which has the ability to spontaneously introduce mutations. This allows mutagenesis of introduced DNAs to modify the polypeptides to have superior functions. In particular, the present inventors revealed the nucleotide sequence of the antibody H chain variable region gene locus of the DT40 cell line. Based on this finding, the present inventors successfully constructed targeting vectors that allow efficient substitution of the antibody H chain variable region gene locus of the DT40 cell line with a gene encoding a desired polypeptide. 1. A method of homologously recombining a DNA construct and a region comprising a DNA encoding an antibody variable region of an antibody-producing cell , which comprises the step of introducing into the antibody-producing cell a targeting vector comprising a DNA construct that comprises:(1) a promoter DNA that functions in the cell;(2) a DNA that encodes a desired amino acid sequence; and(3) a DNA that inhibits the production of a polypeptide comprising the desired amino acid sequence, and can be removed from the DNA construct.2. The method of claim 1 , wherein the DNA of (3) inhibits the production of a polypeptide comprising the desired amino acid sequence claim 1 , and is located between two site-specific recombinase recognition sequences oriented in the same direction claim 1 , and wherein the DNA of (3) comprises a promoter DNA and a marker gene that function in the cell claim 1 , and the DNA of (3) can be removed from the DNA construct by a site-specific recombinase.3. A method for selecting a ...

Подробнее
21-03-2013 дата публикации

Anti-C5 Alpha Antibodies

Номер: US20130071922A1
Принадлежит: Adienne SRL

The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system. 1. An isolated nucleotide sequence encoding for a recombinant human antibody having specificity for a C5 alpha chain of a C5 component of the complement system characterized in that it recognizes a region corresponding to sequence 727-744 (SEQ ID NO: 15) of the C5 component of human complement or a region having at least 80% homology thereto , wherein said antibody inhibits the conversion of the C5 alpha chain to C5a and C5b , wherein a light chain of the antibody is a lambda chain or a kappa chain , and a variable region of a heavy chain is the VH3 region.2. The nucleotide sequence according to claim 1 , wherein said antibody further comprises a peptide tag positioned at the C-terminus of said antibody claim 1 , wherein said tag does not alter the binding specificity to the C5 of said antibody.3. The nucleotide sequence according to claim 1 , wherein said nucleotide sequence is effective in treating a disease selected from the group consisting of a chronic inflammatory disease and an acute inflammatory disease.4. The nucleotide sequence according to claim 3 , wherein said acute inflammatory disease is Multiple Organ Failure or myocardial infarction.5. The nucleotide sequence according to claim 3 , wherein said chronic inflammatory disease is selected from the group consisting of: rheumatoid arthritis claim 3 , glomerulonephritis claim 3 , multiple sclerosis claim 3 , demyelinating peripheral neuropathies claim 3 , and atherosclerosis.6. The nucleotide ...

Подробнее
21-03-2013 дата публикации

Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra

Номер: US20130072546A1
Принадлежит: Curna Inc

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Methionine Sulfoxide Reductase A (MSRA), in particular, by targeting natural antisense polynucleotides of Methionine Sulfoxide Reductase A (MSRA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MSRA.

Подробнее
21-03-2013 дата публикации

Scalable Manufacturing Platform for Viral Vector Purification and Viral Vectors So Purified for Use in Gene Therapy

Номер: US20130072548A1
Принадлежит:

Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use. 1. A method for purifying bona fide AAV vector particles comprising a transgene encoding a therapeutic protein or fragment thereof from an AAV preparation comprising AAV vector particles , empty capsids and host cell impurities , thereby providing an AAV product substantially free of AAV empty capsids , said method comprising:a) harvesting cells comprising recombinant AAV;b) concentrating said cells via Tangential Flow Filtrationc) lysing said cells by microfluidization to form a lysate;d) filtering, thereby clarifying the lysate of step c);e) purifying AAV particles by Ion Exchange Column Chromatography and optionally concentrating column eluate by Tangential Flow Filtration;f) mixing said eluate with cesium chloride and subjecting said mixture to centrifugation, thereby forming a gradient;g) collecting viral particles separated in step f) and subjecting the same buffer exchange by Tangential Flow Filtration;h) formulating purified AAV particles with surfactant to provide an AAV particle formulation;i) filtering said formulation to remove any remaining impurities, wherein said bona fide AAV vector particles are present in said AAV product in an amount of at least 95%.2. The method of claim 1 , wherein said AAV vector particles are present at a concentration of 100 mg/mL.3. The method of claim 1 , wherein said AAV particles of step i) are present at a concentration of 10particles per mL.4. The method of claim 1 , wherein said AAV particles of step i) are present at a concentration of 10particles per mL.5. The method of claim 1 , wherein said AAV particles of step i) are present at a concentration of 10particles per mL.6. The method of claim 1 , wherein said AAV vector particles are derived from an AAV selected from the group consisting of AAV1 claim 1 , AAV2 claim 1 , AAV5 claim 1 , AAV6 claim 1 , AAV8 and AAV9. ...

Подробнее
21-03-2013 дата публикации

Method for optimising gene expression using synonymous codon optimisation

Номер: US20130074218A1
Автор: Ian Hector Frazer
Принадлежит: University of Queensland UQ

The present invention discloses a method for modulating the quality of a selected phenotype that is displayed by an organism or part thereof and that results from the expression of a polypeptide-encoding polynucleotide by replacing at least one codon of that polynucleotide with a synonymous codon that has a higher or lower preference of usage by the organism or part thereof to produce the selected phenotype than the codon it replaces. The present invention is also directed to the use of a codon-modified polynucleotide so constructed for modulating the quality of a selected phenotype displayed by an organism or part thereof.

Подробнее
04-04-2013 дата публикации

Vaccine and methods to reduce campylobacter infection

Номер: US20130084304A1
Принадлежит: University of Arkansas

Vaccine vectors and methods for enhancing resistance to Campylobacter infection or for enhancing the immune response to Campylobacter are provided herein. The vaccine vectors include a first polynucleotide which encodes an antigenic polypeptide selected from SEQ ID NO 7-9 or a fragment thereof. The vector may also include an immunostimulatory polypeptide. The methods include administering the vaccine vectors to a subject.

Подробнее
11-04-2013 дата публикации

B cell activating factor antagonist and preparation method and use thereof

Номер: US20130089549A1
Автор: LI YANG, Yuquan Wei

The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.

Подробнее
25-04-2013 дата публикации

POLYAMINE-CONTAINING POLYMERS AND METHODS OF SYNTHESIS AND USE

Номер: US20130102079A1
Принадлежит: ALBERTA INNOVATES - TECHNOLOGY FUTURES

The present invention relates to polyamine-containing polymers and methods of their synthesis and use. The polymer may be hydroxyethylcellulose, dextran, poly(vinyl alcohol) or poly(methyl acrylate). 1. A method of transfecting a cell with a nucleic acid , comprising contacting the cell with a composition comprising (1) a compound comprising a carbon polymer and one or more polyamine groups , wherein the carbon polymer is selected from the group consisting of hydroxyethylcellulose , dextran , poly(vinyl alcohol) and poly(methyl acrylate); and (2) a nucleic acid.2. A method of introducing an exogenous nucleic acid into a cell , comprising contacting the cell with a composition comprising (1) a compound comprising a carbon polymer and one or more polyamine groups , wherein the carbon polymer is selected from the group consisting of hydroxyethylcellulose , dextran , poly(vinyl alcohol) and poly(methyl acrylate); and (2) a nucleic acid.3. The method of wherein the method is in vitro claim 2 , ex vivo or in vivo. This application is a divisional application of U.S. application Ser. No. 13/078,347 filed Apr. 1, 2011, which claims priority upon U.S. provisional application Ser. No. 61/320,355, filed Apr. 2, 2010. These applications are hereby incorporated by reference in their entireties.The present invention relates to compounds comprising carbon polymers and one or more polyamine groups.Nucleic acids encoding biologically active polypeptides or nucleic acids may be transferred to a cell by any of several methods, including viral vectors and chemical transfection. The choice of technique is a balance between the need to incorporate the nucleic acid efficiently, minimizing impact on the short term, and preferably the long term, survival of the cell, and without compromising the genetic makeup of the cell.Aminated, cationic polymers that interact with the nucleic acid and are then taken up by the cell may be advantageous, at least, by avoiding some of the immunological and ...

Подробнее
02-05-2013 дата публикации

METHOD FOR THE PREPARATION OF HYDROXY ACIDS

Номер: US20130109067A1
Принадлежит: METABOLIC EXPLORER

The present invention concerns a modified microorganism for the biological preparation of an hydroxy acid of formula (I) 114.-. (canceled)16. The microorganism of claim 15 , wherein producing hydroxy-2-keto-acid of formula (II) is improved in said microorganism by increasing the level of expression of at least one of the following enzymes: serine transaminase claim 15 , serine oxidase claim 15 , 3-phosphohydroxypyruvate claim 15 , homoserine transaminase claim 15 , homoserine oxidase claim 15 , 4-oxoglutaryl-CoA synthetase claim 15 , aldehyde reductase/alcohol dehydrogenase.17. The microorganism of claim 15 , wherein the endogenous genes encoding for hydroxy aldehyde reductase activity have been deleted in said microorganism.18. The microorganism of claim 15 , wherein said hydroxy acid of formula (I) is 3-hydroxypropionate and said hydroxy-2-keto-aliphatic acid metabolite of formula (II) is 4-hydroxy-2-ketobutyrate.19. The microorganism of claim 15 , wherein said hydroxy acid of formula (I) is hydroxyacetate and said hydroxy-2-keto-aliphatic acid metabolite of formula (II) is hydroxypyruvate.20. The microorganism of claim 15 , wherein said hydroxy acid of formula (I) is 4-hydroxybutyrate and said hydroxy-2-keto-aliphatic acid metabolite of formula (II) is 5-hydroxy-2-ketopentanoate.21. The microorganism according to claim 15 , wherein said microorganism is selected from the group consisting of bacterium claim 15 , yeast and fungus.22. The microorganism of claim 21 , wherein said microorganism is a bacterium that is selected from the group consisting of Enterobacteriaceae claim 21 , Clostridiaceae claim 21 , Bacillaceae claim 21 , Streptomycetaceae and Corynebacteriaceae.23. A method for the fermentative production of an hydroxy acid of formula (I) claim 21 , comprising:{'claim-ref': {'@idref': 'CLM-00015', 'claim 15'}, 'culturing a microorganism according to , on an appropriate culture medium comprising a source of carbons and'}recovering the hydroxy acid from the ...

Подробнее
02-05-2013 дата публикации

Compositions and Methods for Therapeutic Delivery with Microorganisms

Номер: US20130109568A1
Принадлежит: SEARETE LLC

Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that include modified microorganisms including at least one genetic element encoding at least one therapeutic agent or environmental treatment agent. 1113.-. (canceled)114. A method of administering at least one environmental medium treatment agent to at least one environmental medium , comprising:providing at least one composition to at least one environmental medium;wherein the at least one composition includes at least one modified microorganism including at least one heterologous genetic element encoding at least one environmental medium treatment, and at least one genetic element inducible to initiate death of the at least one modified microorganism.115116.-. (canceled)117. The method of claim 114 , further comprising administering at least one of an inducer or repressor of the heterologous genetic element encoding at least one environmental medium treatment agent.118. The method of claim 114 , further comprising administering at least one of an inducer or repressor of the at least one genetic element inducible to initiate death of the at least one modified microorganism.119. The method of claim 114 , wherein the composition provides an effective amount of at least one environmental medium treatment agent in relation to at least one intended outcome.120. The method of claim 114 , wherein the composition provides an effective amount of at least one environmental medium treatment agent in relation to establishment or re-establishment of organisms in the at least one environmental medium.121. The method of claim 114 , wherein the composition provides an effective amount of at least one environmental medium treatment agent in relation to revitalization of the at least one environmental medium associated with at least one of fire claim 114 , flood claim 114 , contamination claim 114 , drought claim 114 , deforestation claim 114 , temperature change ...

Подробнее
02-05-2013 дата публикации

HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS

Номер: US20130109596A1
Принадлежит: LIFE TECHNOLOGIES CORPORATION

The disclosure generally relates to compositions and methods for the production of nucleic acid molecules. In some aspects, the invention allows for the microscale generation of nucleic acid molecules, optionally followed by assembly of these nucleic acid molecules into larger molecules. In some aspects, the invention allows for efficient production of nucleic acid molecules (e.g., large nucleic acid molecules such as genomes). 1. A multiwell plate for non-template directed synthesis of nucleic acid molecules , the plate comprising:(a) a magnetic bead located in each of a plurality of wells of the plate, and(b) an electrochemically generated acid being present in one or more well, wherein the bead is between 1.0 μm and 100 μm in diameter.2. The multiwell plate of claim 1 , wherein the number of wells in the plate is between 10 and 50 claim 1 ,000.3. The multiwell plate of claim 1 , wherein the total volume of each well is between 0.1 μl and 50 μl.4. The multiwell plate of claim 1 , wherein each well is operably connected to a pair of electrodes.5. The multiwell plate of claim 1 , wherein the wells of the plate are connected to microfluidic channels for the introduction and removal of reagents.6. A method for the generation of an assembled nucleic acid molecule claim 1 , the method comprising:(a) synthesizing a plurality of nucleic acid molecules, wherein each nucleic acid molecule is prepared in a well of a plate in an average amount of from about 0.001 nanomoles to about 1,000 nanomoles;(b) combining the nucleic acid molecules generated in (a) to produce a pool;(c) oining some or all of the nucleic acid molecules present in the pool formed in (b) to form a plurality of larger nucleic acid molecules;(d) eliminating nucleic acid molecules which contain sequence errors from the plurality of larger nucleic acid molecules formed in (c) to produce an error corrected nucleic acid molecule pool; and(e) assembling the nucleic acid molecules in the error corrected nucleic ...

Подробнее
09-05-2013 дата публикации

Reversible, parallel and multitask cloning method and kit

Номер: US20130115658A1
Принадлежит: Individual

The present invention is related to integrated method and tools to construct recombinant DNA molecules (to be used as DNA vaccine or gene therapy) without requiring the use of antibiotic(s) resistance gene(s) and without requiring the addition of one or more antibiotic(s) to the culture medium of cells submitted to this recombinant DNA method. The present invention allows to obtain the selection of recombinant host cell(s) transformed by a (exogenous) nucleic acid sequence of interest (extra-chromosomal vector containing the insert) and simultaneously stabilization (stable inheritance) of this (exogenous) nucleic acid sequence of interest into the transformed host cell(s) descendants (maintenance of the nucleic acid sequence of interest in the host cells population).

Подробнее
16-05-2013 дата публикации

METHODS, COMPOSITIONS AND KITS FOR ONE-STEP DNA CLONING USING DNA TOPOISOMERASE

Номер: US20130122572A1
Принадлежит: DNA TWOPOINTO, INC.

Provided are methods, compositions, and kits for cloning of DNA using DNA topoisomerase. The methods comprise (I) combining into a mixture (A) a first polynucleotide comprising an origin of replication, a selectable marker, two topoisomerase recognition sequences, and two nicking agent recognition sequences, each of the topoisomerase recognition sequences being within 50 nucleotides of at least one of the nicking agent recognition sequences and each of the two nicking agent recognition sequences being nicked, with (B) a sequence-specific topoisomerase and (C) a second polynucleotide having 5′ hydroxyl on each end; and (II) transforming the mixture into a host organism, thereby cloning the second polynucleotide. Formation or purification of a DNA-protein adduct prior to the addition of the second polynucleotide is not required. Also provided are vector sequences to facilitate performance of the methods and methods for modifying a vector of interest to render it useful in the disclosed methods. 121.-. (canceled)22. A composition comprising(i) a first polynucleotide having a first strand and a second strand, wherein said first polynucleotide is a first vector that comprises (a) a stuffer sequence, (b) a first topoisomerase recognition sequence and a second topoisomerase recognition sequence, (c) a first nicking agent recognition sequence and a second nicking agent recognition sequence, and a (d) selectable marker,(ii) a sequence-specific topoisomerase that reversibly cleaves a single strand of double stranded nucleic acid of the first polynucleotide in the presence of said first topoisomerase recognition sequence or said second topoisomerase recognition sequence, and(iii) a second polynucleotide, whereinthe first topoisomerase recognition sequence is in within fifty nucleotides of the first nicking agent recognition sequence,the first topoisomerase recognition sequence is in said first strand and said first nicking agent recognition sequence directs a nicking agent to ...

Подробнее
16-05-2013 дата публикации

Tal effector-mediated dna modification

Номер: US20130122581A1

Materials and Methods related to gene targeting (e.g., gene targeting with transcription activator-like effector nucleases; “TALENS”) are provided.

Подробнее
23-05-2013 дата публикации

SURFACE MARKERS AND USES THEREOF FOR RAPID STABLE CELL LINE GENERATION AND GENE AMPLIFICATION

Номер: US20130130385A1
Автор: Tu Hua
Принадлежит:

The present invention provides methods of producing recombinant cells, methods of large scale production of a gene expression product (such as protein), and methods of establishing a stable cell line using the surface markers. Also provided are expression vectors encoding the surface markers and cells comprising the expression vectors. Further provided are gene expression products (such as proteins) and cells obtained using methods described herein, as well as kits useful for carrying out methods described herein. 1. A method of producing a recombinant cell , comprising: exposing a population of host cells comprising: i) a first nucleic acid sequence comprising a gene of interest , and ii) a second nucleic acid sequence comprising a coding sequence for a surface marker to a separation means that recognizes the surface marker , wherein cells recognized by the separation means can be separated from the rest of the cells.2. A method of large scale production of a gene expression product , comprising exposing a population of host cells comprising: i) a first nucleic acid sequence comprising a gene of interest , and ii) a second nucleic acid sequence comprising a coding sequence for a surface marker to a separation means that recognizes the surface marker , wherein cells recognized by the separation means can be separated from the rest of the cells.3. A method of establishing a stable cell line , comprising exposing a population of host cells comprising: i) a first nucleic acid sequence comprising a gene of interest , and ii) a second nucleic acid sequence comprising a coding sequence for a surface marker to a separation means that recognizes the surface marker , wherein cells recognized by the separation means can be separated from the rest of the cells.4. The method of claim 2 , wherein the surface marker comprises a tag sequence and a transmembrane domain.5. The method of claim 2 , wherein the surface marker comprises a tag sequence and a membrane anchoring region.6. ...

Подробнее
23-05-2013 дата публикации

Methods of Modifying Eurakyotic Cells

Номер: US20130130388A1
Принадлежит: Regeneron Pharmaceuticals, Inc.

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification. 1. A method for targeted insertion of non-endogenous DNA at a desired position in a non-human genome of a eukaryotic cell , comprisingselecting a bacterial artificial chromosome (BAC) clone comprising a large genomic DNA fragment comprising a DNA sequence of interest;employing the BAC clone to generate a large targeting vector comprising the large genomic DNA fragment comprising the DNA sequence of interest;employing the large targeting vector to modify a non-human genome at a desired position with the large targeting vector.2. The method of claim 1 , wherein the non-endogenous DNA is homologous to DNA in the non-human genome at the desired position in the non-human genome.3. The method of claim 1 , wherein the non-endogenous DNA is orthologous to DNA in the non-human genome at the desired position in the non-human genome.4. The method of claim 1 , wherein the non-endogenous DNA comprises unrearranged human immunoglobulin sequences and the desired position is a non-human immunoglobulin locus.5. The method of claim 1 , wherein the non-human genome is a rodent genome.6. The method of claim 5 , wherein the rodent genome is a mouse genome.7. The method of claim 1 , wherein the eukaryotic cell is a mammalian cell.8. The method of claim 1 , wherein the mammalian cell is a ...

Подробнее
30-05-2013 дата публикации

Sequence tag directed subassembly of short sequencing reads into long sequencing reads

Номер: US20130137588A1
Принадлежит: UNIVERSITY OF WASHINGTON

The invention provides compositions and methods for preparing DNA sequencing libraries. In particular, the method relates to preparing DNA sequencing libraries from kilobase scale nucleic acids. The invention also provides methods for assembling short read sequencing data into longer contiguous sequences. The method is useful for various applications in genomics, including genome assembly, full length cDNA sequencing, metagenomics, and the analysis of repetitive sequences of assembled genomes.

Подробнее
30-05-2013 дата публикации

Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf

Номер: US20130137751A1
Принадлежит: Curna Inc

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF.

Подробнее
06-06-2013 дата публикации

MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors

Номер: US20130143911A1
Принадлежит: Dana Farber Cancer Institute Inc

Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.

Подробнее
06-06-2013 дата публикации

Microorganisms and methods for the production of caprolactone

Номер: US20130144029A1
Принадлежит: Genomatica Inc

The invention provides non-naturally occurring microbial organisms containing caprolactone pathways having at least one exogenous nucleic acid encoding a butadiene pathway enzyme expressed in a sufficient amount to produce caprolactone. The invention additionally provides methods of using such microbial organisms to produce caprolactone by culturing a non-naturally occurring microbial organism containing caprolactone pathways as described herein under conditions and for a sufficient period of time to produce caprolactone.

Подробнее
13-06-2013 дата публикации

METHODS FOR MAKING AND USING MOLECULAR SWITCHES INVOLVING CIRCULAR PERMUTATION

Номер: US20130149785A1
Принадлежит: THE JOHNS HOPKINS UNIVERSITY

The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches, expression vectors and host cells for expressing the switches are also provided. 1. A method for assembling a fusion molecule , comprising:generating a circular permutation of an insertion sequence; andinserting the insertion sequence into an acceptor sequence.215-. (canceled)16. A method for modulating a cellular activity , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'providing a fusion molecule generated according to the method of to a cell, wherein a change in state of at least the insertion sequence or the acceptor sequence modulates a cellular activity, and wherein the change in state which modulates the cellular activity is coupled to a change in state of the respective other portion of the fusion molecule; and'}changing the state of the respective other portion of the fusion molecule, thereby modulating the cellular activity.17. A method for delivering a bio-effective molecule to a cell , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'providing a fusion molecule associated with a bio-effective molecule generated according to the method of to the cell, the fusion molecule comprising an insertion sequence and an acceptor sequence, wherein either the insertion sequence or the acceptor sequence binds to a cellular marker of a pathological condition and wherein upon binding to the marker, the fusion molecule dissociates from the bio-effective molecule, thereby delivering the molecule to ...

Подробнее
13-06-2013 дата публикации

Peptide antimicrobials

Номер: US20130150260A1
Принадлежит: WAYNE STATE UNIVERSITY

Provided are methods and compositions for in vivo display and screening of peptides for antimicrobial activity. The methods can include expressing a random peptide library in a microbial cell culture and identifying clones in which microbial cell growth or survival is affected by the peptide expressed by that clone. Also provided are peptide antimicrobials identified using these methods and compositions.

Подробнее
20-06-2013 дата публикации

Albumin fusion proteins

Номер: US20130157933A1
Принадлежит: Individual

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

Подробнее
27-06-2013 дата публикации

Methods and compositions for inactivating glutamine synthetase gene expression

Номер: US20130164785A1
Принадлежит: Sangamo Biosciences Inc

Disclosed herein are methods and compositions for inactivating a glutamine synthetase (GS) gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.

Подробнее
27-06-2013 дата публикации

SELF-DELETING PLASMID

Номер: US20130164790A1
Принадлежит: COBRA BIOLOGICS LTD.

A method of producing a selectable marker gene-free plasmid by culturing a plasmid containing a selectable marker gene flanked by site specific recombinase target sites in a host cell environment incapable of effecting recombination between the site specific recombinase target sites and subsequently culturing the plasmid in another host cell environment which is capable of effecting recombination between the site specific recombinase target sites, so that the selectable marker gene is excised. Uses of plasmids produced by the method for the production of recombinant protein for therapeutic and vaccine purposes, production of therapeutic DNA and DNA vaccines and delivery of recombinant protein and DNA to a patient using live bacterial vectors. 139-. (canceled)40. A method of producing a selectable marker gene-free plasmid comprising the steps of:a) culturing a plasmid containing a selectable marker gene flanked by site specific recombinase target sites selected from Ecdif, cer, psi, pif and mwr in a first host cell environment which is incapable of effecting recombination between the site specific recombinase target sites, wherein the first host cell environment comprises an inactivating mutation in one or more of the genes encoding PepA, ArgR and ArcA; andb) subsequently culturing the plasmid in a second host cell environment which is capable of effecting recombination between the site specific recombinase target sites, such that the selectable marker gene is excised, wherein the second host cell environment contains active versions of PepA and ArgR or ArcA, and comprises a site specific recombinase selected from XerC and XerD.41. The method of further comprising the step of:c) maintaining the selectable marker gene-free plasmid in cell culture.42. The method of further comprising the step of:d) isolating the selectable marker gene-free plasmid from the second host cell environment.43. The method of wherein the first host cell environment and the second host cell ...

Подробнее
27-06-2013 дата публикации

VECTORS FOR DIRECTIONAL CLONING

Номер: US20130164837A1
Принадлежит: PROMEGA CORPORATION

The invention provides vectors and methods for directional cloning. 1. A vector comprising a SgfI recognition site 5′ to an opening reading frame which begins with an ATG and ends with an in-frame stop codon provided by nucleotides TAA in a PmeI recognition site.2. The vector of wherein the first and third recognition sites are cleaved by SgfI and yield an exchange site comprising GCGATCGCnATGG (SEQ ID NO: 92) claim 1 , wherein n is C claim 1 , A claim 1 , T or G.3. The vector of wherein n is C.4. The vector of which further comprises a promoter 5′ to the SgfI site.5. A vector prepared by ligatinga DNA fragment comprising an opening reading frame which begins with an ATG but has no in-frame stop codon, a 5′ end generated after cleavage of a first recognition site with a first restriction enzyme which generates an end compatible with an end generated after cleavage of a SgfI recognition site by SgfI, and a 3′ end generated after cleavage of a second recognition site with a second restriction enzyme which generates a blunt end, anda DNA segment comprising a 5′ end generated after cleavage of PmeI recognition site by PmeI and a 3′ end generated after cleavage of a third recognition site with a third enzyme which generates an end compatible with an end generated after cleavage of a SgfI recognition site by SgfI,wherein the first restriction enzyme is SgfI, the third restriction enzyme is SgfI, or both the first and third restriction enzymes are SgfI, and wherein ligation of the blunt end and the 5′ end generated after cleavage of the PmeI site provides an in-frame TAA stop codon for the open reading frame.6. The vector of wherein the first and third recognition sites are cleaved by SgfI and yield an exchange site comprising GCGATCGCnATGG (SEQ ID NO: 92) claim 5 , wherein n is C claim 5 , A claim 5 , T or G.7. The vector of wherein n is C.8. The vector of which further comprises a promoter 5′ to the exchange site formed by ligation of the SgfI compatible ends.9. A vector ...

Подробнее
11-07-2013 дата публикации

NOVEL REGULATORY ELEMENTS

Номер: US20130177943A1
Автор: ENENKEL Barbara

The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines. 116.-. (canceled)17. An isolated polyadenylation signal comprising a nucleic acid comprising a sequence at least 75% identical to the sequence of SEQ ID NO:9.18. The polyadenylation signal according to comprising a sequence at least 80% identical to the sequence of SEQ ID NO:9.19. The polyadenylation signal according to comprising a sequence at least 85% claim 17 , 90% claim 17 , 95% or 98% identical to the sequence of SEQ ID NO:9.20. The polyadenylation signal according to comprising the sequence of SEQ ID NO:9.21. The polyadenylation signal according to wherein said polyadenylation signal is operably linked to a heterologous coding sequence.22. A vector comprising a polyadenylation signal comprising a nucleic acid comprising a sequence at least 75% identical to the sequence of SEQ ID NO:9.23. The vector of comprising a heterologous gene of interest encoding for a heterologous product of interest.24. The vector of claim 23 , wherein the product of interest is a polypeptide of interest and said polypeptide of interest is an antibody claim 23 , antibody fragment or fusion protein.25. The vector of comprising a sequence at least 80% identical to the sequence of SEQ ID NO:9.26. The vector of comprising a sequence at least 85% claim 22 , 90% claim 22 , 95% or 98% identical to the sequence of SEQ ID NO:9.27. The vector of comprising the sequence of SEQ ID NO:9.28. A cell comprising the vector of .29. The cell according to claim 28 , wherein said polyadenylation signal is operably linked to a transcription unit encoding a product of ...

Подробнее
11-07-2013 дата публикации

Tnf superfamily collectin fusion proteins

Номер: US20130178604A1
Принадлежит: Apogenix AG

The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.

Подробнее
18-07-2013 дата публикации

METHOD FOR PRODUCING VIRUS VECTOR

Номер: US20130183719A1
Принадлежит:

The present invention provides a method for producing a virus vector, which comprises a step wherein cells that are capable of producing a virus vector are cultured in a culture medium that contains, as active components, a retinoic acid and a histone deacetylase inhibiting substance; and a culture medium for the production of a virus vector, which is characterized by containing, as active components, a retinoic acid and a histone deacetylase inhibiting substance. 1. A method of producing a virus vector , which comprises a step of culturing a cell capable of producing the virus vector in a culture medium containing retinoic acid and a histone deacetylase inhibitor as active ingredients.2. The method according to claim 1 , wherein the culture medium further contains lipid as an active ingredient.3. The method according to claim 1 , wherein the cell is a cell capable of producing the virus vector continuously.4. The method according to claim 1 , wherein the virus vector is a retrovirus vector.5. The method according to claim 1 , wherein the histone deacetylase inhibitor is at least one substance selected from the group consisting of trichostatin A and sodium butyrate.613-. (canceled)14. A method of producing a transformed cell population claim 1 , which comprises a step of producing a virus vector by the method according to claim 1 , and a step of transforming a cell with the virus vector produced in the above step.15. A culture medium for production of a virus vector claim 1 , containing 1 nM to 10 μM all-trans-retinoic acid claim 1 , and either 10 nM to 50 μM trichostatin A or 1 nM to 50 mM sodium butyrate claim 1 , as active ingredients. The present invention relates to a method of producing a virus vector and a culture medium for production of a virus vector.Gene therapy using a virus vector has been developed for the purposes of treating cancer and infection disease as well as congenital genetic disease, and many clinical trials have been conducted. In particular ...

Подробнее
18-07-2013 дата публикации

Vectors for directional cloning

Номер: US20130183760A1
Принадлежит: Promega Corp

The invention provides vectors and methods for directional cloning.

Подробнее
18-07-2013 дата публикации

Bacterial surface display and screening of thioether-bridge-containing peptides

Номер: US20130184177A1
Автор: Tjibbe Bosma
Принадлежит: LanthioPep BV

The invention relates to bacterial cell surface display of post-translationally modified heterologous proteins. Provided is an isolated nucleic acid construct encoding a proteinaceous substance comprising, from the N-terminus to the C-terminus, at least (a) an N-terminal a lantibiotic leader sequence; (b) an amino acid sequence of interest to be post-translationally modified to a dehydroresidue- or thioether-bridge containing polypeptide; (c) a hydrophilic cell-wall spanning domain; (d) a sortase recognition motif; (e) a hydrophobic membrane spanning domain and (f) a C-terminal charged membrane anchoring domain. Also provided is a Gram-positive host cell expressing the construct, as well as a library of host cells.

Подробнее
25-07-2013 дата публикации

HUMANIZED IMMUNOGLOBULIN LOCI

Номер: US20130189774A1
Принадлежит: THERAPEUTIC HUMAN POLYCLONALS, INC.

The present invention concerns methods and means to produce humanized antibodies from transgenic non-human animals. The invention specifically relates to novel immunoglobulin heavy and light chain constructs, recombination and transgenic vectors useful in making transgenic non-human animals expressing humanized antibodies, transgenic animals, and humanized immunoglobulin preparations. 1. A B cell from a transgenic animal generating antibody diversity primarily by gene conversion and/or hypermutation , wherein said transgenic animal comprises a humanized immunoglobulin (Ig) locus present in a transgenic vector , wherein said humanized Ig locus is derived from an Ig locus or a portion of an Ig locus of an animal generating antibody diversity primarily by gene conversion and/or hypermutation , comprising multiple Ig gene segments wherein:(a) at least one of said gene segments is a human Ig gene segment flanked by nucleotide sequences comprising at least about 20 contiguous nucleotides from a spacer sequence from an immunoglobulin heavy or light chain gene of said animal generating antibody diversity primarily by gene conversion and/or hypermutation, or from a consensus sequence of two or more of said spacer sequences;(b) said gene segments are juxtaposed in an unrearranged, partially rearranged or fully rearranged configuration, and(c) said humanized Ig locus is capable of undergoing gene rearrangement, if necessary, and gene conversion and/or hypermutation, and producing a repertoire of humanized immunoglobulins in said transgenic animal.2. The B cell of claim 1 , wherein said transgenic animal is a transgenic rabbit.3. The B cell of or claim 1 , wherein said humanized Ig locus comprises multiple Ig gene segments wherein at least one of said gene segments is a human Ig gene segment comprising two or more identical or different units consisting of claim 1 , from 5′ to 3′ direction claim 1 , a 5′ nucleotide sequence claim 1 , a human Ig heavy or light chain V gene ...

Подробнее
25-07-2013 дата публикации

Methods, Systems And Compositions Related To Reduction Of Conversions Of Microbially Produced 3-Hydroxyproplonic Acid (3-HP) To Aldehyde Metabolites

Номер: US20130189787A1
Принадлежит: OPX Biotechnologies Inc

The present invention relates to methods, systems and compositions, including genetically modified microorganisms, directed to achieve decreased microbial conversion of 3-hydroxypropionic acid (3-HP) to aldehydes of 3-HP. In various embodiments this is achieved by disruption of particular aldehyde dehydrogenase genes, including multiple gene deletions. Among the specific nucleic acids that are deleted whereby the desired decreased conversion is achieved are aldA, aldB, puuC), and usg of E. coli. Genetically modified microorganisms so modified are adapted to produce 3-HP, such as by approaches described herein.

Подробнее
01-08-2013 дата публикации

Poxvirus Expression System

Номер: US20130195912A1
Принадлежит: Oxford University Innovation Ltd

There is provided a method for inserting a nucleic acid sequence that encodes a foreign peptide into a poxvirus genome, said method comprising: identifying in the poxvirus genome a poxvirus open reading frame wherein said open reading frame is characterised by an initial ATG start codon and wherein expression of said open reading frame is driven by an operably-linked poxvirus promoter located upstream of the open reading frame and wherein expression of said open reading frame provides a peptide that is non-essential to viability of the poxvirus; and inserting the nucleic acid sequence that encodes the foreign peptide at a position downstream of the poxvirus promoter; wherein following said insertion, (i) the nucleic acid that encodes the foreign peptide is operably-linked to the poxvirus promoter and expression of said nucleic acid is driven by said poxvirus promoter; and (ii) translation of the foreign peptide is initiated at an ATG start codon located at the same position as the ATG start codon of the poxvirus open reading frame. Also provided are a poxvirus vector and corresponding uses of the poxvirus vector in medicine.

Подробнее
01-08-2013 дата публикации

Expression Of Positive Sense Single Stranded RNA Virus And Uses Thereof

Номер: US20130195914A1
Автор: Dhar Arun K.
Принадлежит: Viracine Therapeutics Corporation

The invention relates to the fields of viruses, vaccines and compounds and methods for expression. In particular, the invention includes methods and agents capable of producing quantities of a vaccine to a positive sense single stranded RNA (“(+)sense RNA”)virus. 1. A baculovirus capable of infecting a facilitating host comprising a DNA sequence that codes for a functional positive sense single stranded RNA viral genome (“(+)sense RNA”) that is not capable of infecting said facilitating host , wherein the transcription of said DNA sequence is under the control of a single promoter.2. The baculovirus of claim 1 , wherein said genome of said functional (+)sense RNA virus will not replicate in said facilitating host unless part of the genome of said baculovirus.3. The baculovirus of wherein said facilitating host is an insect cell.4. The baculovirus of wherein said single promoter is a promoter functional in an insect cell.5. The baculovirus of claim 1 , wherein said host of said functional (+)sense RNA virus is a human cell.68.-. (canceled)9. The baculovirus of claim 1 , wherein said DNA sequence codes for a structural and non-structural genes sufficient for infection in its host cell.1011.-. (canceled)12. The baculovirus of further comprising a second DNA sequence that codes for a sub-genomic component of said functional (+)sense RNA virus.13. The baculovirus of claim 12 , wherein said second DNA sequence further comprises a second promoter.1422.-. (canceled)23. A composition comprising a first virus capable of infecting a facilitating host comprising a first DNA sequence that codes for a (+)sense RNA viral genome or complement thereof that is not capable of infecting said facilitating host and a second DNA sequence coding for a baculovirus genome capable of infecting said facilitating host claim 12 , wherein the expression of said first DNA sequence is under the control of a single promoter.24. The composition of claim 23 , wherein said second DNA sequence further ...

Подробнее
01-08-2013 дата публикации

Double-Stranded RNA Oligonucleotides Which Inhibit Tyrosinase Expression

Номер: US20130195966A1
Принадлежит: LOreal SA

Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 μm in size, having a zeta potential of from 10 to 80 mV.

Подробнее